Chris Roop, head of M&A for the Americas at investment bank Jefferies, said Big Pharma will be looking for new drugs to boost growth in 2025.GP Kidd/Getty ImagesA top M&A banker said Big Pharma will be on the hunt for more acquisitions in 2025.Major drugs including Keytruda and Eliquis will see patent exclusivity expire in coming years.Pharma companies look at areas such as obesity to supplement growth, Jefferies' Chris Roop said.Big Pharma will hunt for more acquisitions in 2025 as industry giants face patent expiration for some of their best-selling drugs, according to a top M&A banker.Merck's cancer drug Keytruda, the top-selling medication in the world, will lose patent exclusivity at the end of 2028.Eliquis, made by Pfizer and Bristol-Myers Squibb to treat and prevent blood clots, will lose its exclusivity earlier that same year.